ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
8.27
-0.10 (-1.19%)
At close: Jul 24, 2026, 4:00 PM EDT
8.22
-0.05 (-0.58%)
After-hours: Jul 24, 2026, 7:46 PM EDT
ADMA Biologics Revenue
ADMA Biologics had revenue of $114.49M in the quarter ending March 31, 2026, a decrease of -0.27%. This brings the company's revenue in the last twelve months to $509.86M, up 10.99% year-over-year. In the year 2025, ADMA Biologics had annual revenue of $510.17M with 19.63% growth.
Revenue (ttm)
$509.86M
Revenue Growth
+10.99%
P/S Ratio
3.76
Revenue / Employee
$788,043
Employees
647
Market Cap
1.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 510.17M | 83.72M | 19.63% |
| Dec 31, 2024 | 426.45M | 168.24M | 65.15% |
| Dec 31, 2023 | 258.22M | 104.14M | 67.59% |
| Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
| Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
| Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
| Dec 31, 2019 | 29.35M | 12.36M | 72.79% |
| Dec 31, 2018 | 16.99M | -5.78M | -25.37% |
| Dec 31, 2017 | 22.76M | 12.10M | 113.49% |
| Dec 31, 2016 | 10.66M | 3.48M | 48.53% |
| Dec 31, 2015 | 7.18M | 1.26M | 21.33% |
| Dec 31, 2014 | 5.92M | 2.85M | 92.84% |
| Dec 31, 2013 | 3.07M | 1.95M | 174.35% |
| Dec 31, 2012 | 1.12M | 357.08K | 46.92% |
| Dec 31, 2011 | 761.04K | - | - |
| Jun 30, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Aurinia Pharmaceuticals | 298.30M |
| Syndax Pharmaceuticals | 217.17M |
| Ocular Therapeutix | 52.04M |
| Monte Rosa Therapeutics | 42.95M |
| Precigen | 31.60M |
| Zenas BioPharma | 10.00M |
ADMA News
- 21 hours ago - $ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law - GlobeNewsWire
- 9 days ago - Adma Biologics price target lowered to $17 from $20 at Mizuho - TheFly
- 10 days ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMA - GlobeNewsWire
- 18 days ago - $ADMA Fraud Notification: ADMA Biologics Sued for Securities Fraud After Channel Stuffing Claims Spark a 29% Stock Drop – Investors Notified to Contact BFA Law by August 10 - GlobeNewsWire
- 22 days ago - ADMA INVESTOR REMINDER: ADMA Biologics, Inc. Investors Have Until August 10, 2026 To Seek Lead Plaintiff Role - Business Wire
- 24 days ago - ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - GlobeNewsWire
- 4 weeks ago - ADMA BIOLOGICS, INC. (ADMA) INVESTOR ALERT Investors With Large Losses in ADMA Biologics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewsWire
- 4 weeks ago - Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders - Newsfile Corp